《半新股》永泰生物(06978.HK)续挫19%屡创上市新低
半新股永泰生物-B(06978.HK)连续第六天寻底,尤其是今天曾急挫近24%低见6.8元上市新低,现造7.18元,急挫19%,一向薄弱成交倍增至247万股,创逾两个月高,涉资1,917万元。
永泰是内地一家领先细胞免疫治疗生物医药公司。股份於今年7月以每股11元来港上市,股价於首挂日曾升至16.86元遇阻,之後反覆回落,近日更屡创上市新低。该公司8月下旬公布,截至6月底止中期亏损按年扩大2.4倍至1.74亿元人民币(下同),每股亏损0.46元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.